You are here

  • Home
  • Archive
  • Volume 19, Issue 3
  • Meta-analysis finds benefit for dual antiplatelet therapy but limitations preclude changing standard mono antiplatelet therapy approach for acute non-cardioembolic ischaemic stroke or transient ischaemic attack

Article Text

Article menu
Download PDFPDF
Therapeutics
Systematic review and meta-analysis
Meta-analysis finds benefit for dual antiplatelet therapy but limitations preclude changing standard mono antiplatelet therapy approach for acute non-cardioembolic ischaemic stroke or transient ischaemic attack
  1. Wilbert S Aronow
  1. Division of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, New York, USA
  1. Correspondence to : Dr Wilbert S Aronow, Division of Cardiology, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595, USA; wsaronow{at}aol.com

http://dx.doi.org/10.1136/eb-2013-101649

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Wong KSL, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack. An updated systematic review and meta-analysis. Circulation 2013;128:1656–66.OpenUrlAbstract/FREE Full Text

    Context

    Current guidelines recommend aspirin, aspirin plus clopidogrel or aspirin plus extended-release dipyridamole for treatment of acute ischaemic stroke (IS) or transient ischaemic attack (TIA) to prevent recurrent stroke, myocardial infarction and cardiovascular death.1 The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial randomised 5170 Chinese patients within 24 h after the onset of IS or TIA to clopidogrel plus aspirin versus aspirin plus placebo for 90 days. Clopidogrel plus …

    View Full Text

    Footnotes

    • Competing interests None.